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Arbor, Michigan, USAIntroduction: The number of persons receiving renal replacement therapy (RRT) is estimated at more than
2.5 million worldwide, and is growing by 8% annually. Registries in the developing world are not up to
standards compared to the United States Renal Data System (USRDS). Herein we examine the causes,
progression, and magnitude of end-stage kidney disease (ESKD) over 3 decades in Oman.
Methods: We examined ESKD data from 1983 to 2013. Data from 1998 to 2013 were obtained through an
Information Management System. Data before 2008 were collected from patients’ ﬁles. A questionnaire
based on USRDS form 2728 was completed by nephrologists once a citizen reached ESKD.
Results: A total of 4066 forms were completed, with a response rate of 90% (52% male). The mean (SD)
age was 50.1 (14.0) years. By 31 December 2013, there were 2386 patients alive on RRT, of whom 1206
were on hemodialysis (50.5%), 1080 were living with a functioning kidney transplant (45.3%), and 100 were
receiving peritoneal dialysis (4.2%). The incidence of ESKD on RRT was 21, 75, and 120 per million pop-
ulation in 1983, 2001, and 2013, respectively. Similarly, the prevalence of ESKD was 49, 916, and 2386 in
1983, 2001, and 2013 respectively. Among patients with ESKD on RRT, a progressive rise was seen in
diabetic nephropathy, with 5.8%, 32.1%, and 46% in 1983, 2001, and 2013 respectively.
Discussion: The incidence and prevalence of ESKD has increased progressively over last 30 years. This is
anticipated to continue at an even higher rate in view of the progressive rise in noncommunicable dis-
eases. Continuous improvement in registries is required to improve capturing of ESKD patients for
providing accurate data to health authorities, and enhancing public awareness of the magnitude, future
trends, treatments, and outcomes regarding ESKD.
Kidney Int Rep (2017) 2, 27–35; http://dx.doi.org/10.1016/j.ekir.2016.09.001
KEYWORDS: End-stage kidney disease (ESKD); peritoneal dialysis; renal transplant; renal replacement therapy (RRT);
renal registry, Oman
ª 2016 International Society of Nephrology. Published by Elsevier Inc. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).W orldwide, the number of persons receiving renalreplacement therapy (RRT) is estimated at more
than 2.5 million, with the incidence growing by
approximately 8.0% annually.1,2
Hypertension and diabetes are considered key risk
factors for developing end-stage kidney disease (ESKD)
in the developed world, and necessitate eventual
management with RRT.3 The number of diabetic per-
sons worldwide among adults $20 years of age was
estimated to be w171 million in the year 2000 and is
expected to reach 366 million by 2030.4,5
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International Reports (2017) 2, 27–35of persons with diabetes has increased substantially,
from approximately 15 million in 2000 to around
26 million in 2010, with an expectation of exceeding
42 million by 2030.4,6 In the GCC, according to the
2014 update to the International Diabetes Federa-
tion (IDF) Diabetes Atlas, the comparative diabetes
prevalence (i.e., calculated using the age proﬁle of
the world population) was 21.9% in Bahrain, 23.1%
in Kuwait, 14.5% in Oman, 19.8% in Qatar, 23.9%
in Saudi Arabia, and 19.0% in the United Arab
Emirates.7
Similar to Diabetes Globally, the overall prevalence
of elevated blood pressure (prehypertension and hy-
pertension) in adults aged 25 years and more was
approximately 40% in 2008, with the number of per-
sons with uncontrolled hypertension rising from 600
million in 1980 to nearly 1 billion in 2008.8,9
These recent ﬁgures are very alarming. They have
signiﬁcant implications for future medical services27
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Figure 1. Age distribution of end-stage kidney disease (ESKD)
patients over 30 years and in 2013.
CLINICAL RESEARCH F Al Ismaili et al.: End-Stage Kidney Disease in Omanrequiring RRT care, and associated burdens on many
aspects of the health care system related to providing
the necessary care for persons with various complica-
tions of noncommunicable chronic diseases such as
ESKD. Registries that report data relating to complica-
tions, as well as the incidence and prevalence of non-
communicable diseases, are of great importance for
health providers. The United States Renal Data System
(USRDS) is one of the leading registries that collects,
analyzes, and distributes information about ESKD, and
provides an international comparison through collab-
oration with registries around the world, including the
registry from Oman.
Many of the developing countries lack complete and
accurate information about ESKD and the different
perspectives related to it, including Oman. This paper
examines ESKD status and provides future perspectives
related to ESKD in Oman for its citizens through anal-
ysis of trends during these past 3 decades.
METHODS
This descriptive study examined the data that have
been obtained through a well-recognized, internation-
ally awarded Omani comprehensive electronic Hospital
Information Management System, between 1983 and
2013, in Oman. In addition, a questionnaire based on
the USRDS 2728 data collection form was used in all
renal dialysis units (RDU) across Oman and have been
obligatorily completed by nephrologists once a citizen
reached ESKD (Supplementary Figure S1). These
completed forms were sent to a centralized data
collection system in the main RDU in Muscat.
The Information received from each RDU was
checked and entered by nephrologists into a database
located in the central RDU in Muscat, using the com-
puter software program Microsoft Access (Microsoft
Corporation, Redmond, WA). The data entered are
rechecked by 2 other team members. The data collected
include the following: name of the RDU, name of the
patient, civil identity number, hospital number, phone
number, sex, date of birth, residency, marital status,
education level, dry weight and height, primary cause
of ESKD, comorbid conditions, type of dialysis at ESKD
initiation, dialysis start date, complete blood count,
bone proﬁle, liver function test proﬁle, intact para-
thyroid hormone level, iron proﬁle, and glucose and
lipid proﬁles at the start of RRT. In addition, data were
collected regarding the virology proﬁle including HIV,
and hepatitis B and C.
The complete data have been collected appropriately
for the registry throughout each year since 1998. Data
before that were collected and added to the registry
retrospectively from patient ﬁles from the only single28dialysis center that existed in the country from 1983 to
1997. Data were analyzed using STATA software (Stata
Corporation, College Station, TX).
RESULTS
Over a period of 30 years, 4066 completed data forms
were received by the centralized data collection unit in
Muscat, with a response rate of 90%. Of the patients
represented, 2104 were male (52%) and 1962 were fe-
male (48%). As shown in Figure 1, age ranged from 1 to
90 years in the last 30 years, with an overall mean age
(SD) of 50.1 (14.0) years whereas it was 53.1 (15.2) years
in 2013. About two-thirds of the population were
married and 100% were living with a spouse, family,
or friends. Only one-tenth had a college education, one-
fourth had a secondary school education, and almost
two-thirds had less than 12 years of education. Less
than one-ﬁfth of them were employed, less than one-
ﬁfth were retired, almost one-half were unemployed,
and the remaining individuals were either disabled or
of unknown status.
Figure 1 also shows that the percentage of persons
aged 65 to 75 years has increased from 10.9% to 17.0%;
conversely, the percentage of persons aged 20 to 44
years in 2013 has declined to 25.0% from 33.6% over
the last 30 years. By 31 December 2013, there were 2386
patients alive and on RRT, of whom 1206 were
receiving hemodialysis (50.5%), 1080 were living with
a functioning kidney transplant (45.3%), and 100 were
undergoing peritoneal dialysis (4.2%). In terms of
comorbidities, 87% of the RRT patients had hyper-
tension, 58% had diabetes, 27% had IHD, 3% had
cerebovascular disease, and 0.8% had respiratory dis-
ease. Also, 2.0% had right below-knee amputation, and
1.0% had bilateral below-knee amputation. Similarly,
2.0% of the RRT population had bilateral blindness,
1% had unilateral blindness, and 10.0% had weakKidney International Reports (2017) 2, 27–35
F Al Ismaili et al.: End-Stage Kidney Disease in Oman CLINICAL RESEARCHvisual disturbances. In addition, 2.0% of RRT patients
had diabetic gastroenteropathy.
Regarding antihypertensive medications among RRT
patients, 17% had no medication, 49.0% had 1 medica-
tion, 29.0% had 2 medications, 3.0% had 3 medications,
and 2.0% had 4 medications. Antihypertension
medications were variable: 7% of patients were on
a-blockers, 42% were on b-blockers, 4% were
on angiotensin converting enzyme inhibitors, 2% were
on angiotensin receptor blockers, and 69% were on
calcium channel blockers. Approximately 3.0% of RRT
patients were positive for hepatitis B virus, 6% for
hepatitis C, and 2% for both hepatitis B and C virus
infection. Regarding anemia management: 86% of dial-
ysis patients were on erythropoiesis-stimulating agents,
and 70%were on iron supplements, of whom 70%were
on i.v. iron and 30%were on oral iron. All patients were
on treatment for anemia. Similarly, management of
metabolic bone disease was reported, and showed that
80% of dialysis patients were on phosphate binders and
40% were on vitamin D supplementation.
Clinical parameters were reported for all RRT pa-
tients. The mean (SD) height was 161.3 (11.1) cm, with
a range of 118 to 187 cm; dry weight was 65.3 (18.5) kg,
with a range of 23.0 to 140.0 kg; and body mass
index (BMI) was 25.02 (6.4), with a range of 14.0 to
49.0. The mean (SD) systolic blood pressure was
150.7 (23.7) mm Hg; diastolic blood pressure was
82.05 (11.4) mm Hg; and mean arterial pressure was
105.2 (11.7) mm Hg. Laboratory data showed that21
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Figure 2. Incidence of end-stage kidney disease (ESKD) per million popu
Kidney International Reports (2017) 2, 27–35mean (SD) for sodium (Na) was 140.0 (13.0); potassium
(K) was 4.67 (0.92); urea was 27.2 (10.2); serum creati-
nine (SCr) was 739.9 (254), bicarbonate was 18.5 (4.41);
chloride was 97.5 (10.5); hemaglobin (Hb) was 9.50
(1.18); hematocrit (Hct) was 28.4 (5.3); total cholesterol
was 153 (151) mg/dl; ferritin was 304; transferrin
saturation (TSAT) was 27.2% (30); protein was 68.2
(8.2); and albumin was 31.1 (5.9). Blood groups were
reported as A, 20.0%; B, 27.0%; AB, 6.0%; and group
O, 47.0%.
Figures 2 and 3 show the progressive increase in the
incidence and prevalence of patients with kidney dis-
ease who received RRT. The incidence during 1983 was
very low (21 per million population [PMP]) and has
been gradually increasing (75 PMP in 2001 and 120
PMP in 2013) as shown in Figure 2. Similarly, as in
Figure 3, the prevalence of ESKD on RRT in 1983 was
49 which increased to 916 in 2001 and reached 2386
in 2013.
As shown in Figure 4, among all the patients with
ESKD on RRT, there was a progressive rise in the
percentage of patients with diabetic nephropathy from
1983 until the end of 2013, comprising 5.8%, 32.1%,
and 46% of all patients in 1983, 2001, and 2013,
respectively.
As shown in Figure 5, over the 30-year period from
1983 to 2013, the primary cause of ESKD among pa-
tients receiving RRT was chronic glomerulonephritis
(35%), followed by diabetes (28%), hypertension
(18%), and other causes (19%).63
75
76
95
100
103
108
120
s
lation (PMP) over 30 years.
29
49 
115 
154 
238 
315 
427 524 
627 770 
916 1093 
1223 
1497 
1548 
1818 
2386 
0 
500 
1000 
1500 
2000 
2500 
3000 
No.of paƟents 
Years
Figure 3. Total number of end-stage kidney disease (ESKD) patients on renal replacement therapy (RRT) over 30 years.
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lation during 2013, diabetes was the leading cause of
ESKD (46%), followed by hypertension (22%), and
chronic glomerulonephritis (18%). The reported data
regarding hemodialysis show that 90% of patients
underwent dialysis 4 hours 3 times weekly, and 8% for
3 hours 3 times weekly, and the frequency of dialysis0
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Figure 4. Trend of diabetic nephropathy in Oman over a 30-year period.
30in these patients varied. Of the dialysis population,
almost 80% started dialysis via catheter, and less than
20% had a permanent vascular access (arteriovenous
ﬁstula). The mean (SD) period from the start of dialysis
until arteriovenous ﬁstula creation was 100.9 (167)
days, with a range of 5 to 798 days. Dialysis patient
survival was reported and showed that the mean (SD)46%
Kidney International Reports (2017) 2, 27–35
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Figure 5. Etiological classiﬁcation of end-stage kidney disease
(ESKD) patients on renal replacement therapy (RRT) over a 30-year
period, and current etiological classiﬁcation of ESKD patients on
hemodialysis. CGN, chronic glomerulonephritis; DM-N, diabetic ne-
phropathy; HTN–N, hypertensive nephropathy; OTH, others including
urological causes, tubulointerstitial and vascular, hereditary, and
congenital kidney disease.
F Al Ismaili et al.: End-Stage Kidney Disease in Oman CLINICAL RESEARCHwas 9.13 (5.8) years, with a range of 3 to 32 years. The
mortality rate was ranged from 50 to 70 patients per
year, from the following causes: cardiovascular, 40%;
cerebrovascular, 13%; infections; 18%; gastrointestinal
(bleeding), 10%; hepatic, 9%; and others, 10%.
DISCUSSION
This is the ﬁrst paper to report the causes, progression,
and magnitude of ESKD over the last 3 decades in
Oman. The study showed that the majority of ESKD
patients in Oman were young and had an equal sex
distribution. Our results indicated a large fraction of
patients living with a kidney transplant, almost equal
to those who have been on dialysis. Having such a
large fraction of ESKD patients living with a kidney
transplant has been reported for only a relatively small
percentage of countries (<30%) worldwide. The cur-
rent study ﬁndings also clearly show a progressive rise
in the ESKD incidence and prevalence over the 30 years
from 1983 to 2013. The main cause of ESKD has
changed over this time period, from glomerulonephritis
as the major cause in 1983 to diabetic nephropathy
during the last few years.
As of 2013, the USRDS reported that the lowest
treated ESKD incidence rates ranged from 45 to 96 PMP
in Bangladesh, Russia, Estonia, Iran, Iceland, Ireland,
Finland, Switzerland, and Scotland. This is lower than
the incidence rate of 120 PMP calculated for Oman in
2013. However, other countries such as Taiwan, the
Jalisco region of Mexico, and the United States re-
ported the highest incidence of treated ESKD, at 458,
421, and 363 PMP, respectively.
In an effort to standardize the data collection in
Oman and to provide the opportunity for internationalKidney International Reports (2017) 2, 27–35comparisons, the Oman registry questionnaire has been
developed to be similar to the 2728 USRDS form. There
is, however, no uniformity of data collection in all
registries worldwide. Large differences are also seen
across countries in regard to the incidence and preva-
lence of ESKD, even among various high-standard
registries. This may reﬂect differences in risk factors
and prevalence of chronic kidney disease (CKD), its
progression in each region, and the contributing fac-
tors, both medical and socioeconomic.10–12
Almost 40,000 persons aged 40 years or more were
screened for CKD in a preliminary survey performed in
2009 throughout Oman. Of the individuals screened,
0.9% had severe renal failure, with an estimated
glomerular ﬁltration rate of less than 30 ml/min/1.73 m2;
9% had moderate renal failure with estimated glomer-
ular ﬁltration rates between 30 and 59 ml/min/1.73 m2;
and 29% had mild renal failure with estimated glomer-
ular ﬁltration rates of 60 to 90 ml/min/1.73 m2 (unpub-
lished data). Further study in that regard has been
ongoing.
In the next few years, it would be of great value to
assess the rate of progression from CKD to ESKD and
whether the progression rate is as high as in the United
States or lower, as in Europe.13 In addition, this may
provide a better understanding of the reasons for and
contributors to the speciﬁc rate of progression to ESKD
in Oman. If this high CKD incidence is to be followed
by a rapid rate of progression, with short duration in
each stage of CKD, it is probable that we are seeing only
the tip of the iceberg of ESKD with RRT. The nature of
the relationship between CKD and ESKD is multifac-
eted, and many risk factors interact in a complex way
that may ultimately determine its incidence and prev-
alence and the progression toward ESKD across various
populations. However, based on our data showing the
continuing large increase in the prevalence of treated
ESKD in Oman, the picture looks grim, with a high
prevalence of CKD at the present time.
We predict that, in the coming decades, a high
percentage of the population will be suffering from
noncommunicable diseases and complications such as
CKD and ESKD. The health system may not be able to
bear the burden and sustain provision of the current
comprehensive, government-paid, free service to its
citizens in Oman. Therefore, other strategies to curtail
the progression of CKD, such as by providing and
optimizing the standard of care for pre-ESKD patients
and controlling various risk factors, are of paramount
importance for any future health care planning.14
In Oman in 2013, the majority of patients (80%)
were younger than 64 years of age, compared to the
United States, where only 60% of patients were31
CLINICAL RESEARCH F Al Ismaili et al.: End-Stage Kidney Disease in Omanyounger than 64 years at the time of initiating RRT for
ESKD.15 In Japan, the average age of dialysis patients
was almost 67 years in 2013, with an increase in the
number of dialysis patients being largely due to the
growth in the fraction of patients who were >65 years
of age15,16 whereas, in Europe, the mean age was 62.0
years.16,17 In the Gulf Cooperation Council (GCC)
countries, the most prevalent age group has been be-
tween 33 and 60 years, with the middle-aged group
constituting the majority of the dialysis population,
and elderly patients (those aged >65 years) consti-
tuting only 3%.18 It is expected that there will be a
shift of the percentage of ESKD patients on RRT toward
older age groups in the coming years, as their pro-
portion of the overall population and their life expec-
tancy are increasing. A glimpse of this is now seen in
the present paper, as per 2013 data.
The present study showed very little difference
between the sexes, with males constituting 52% and
females 48% among all ESKD patients; in comparison,
the USRDS data showed that males contribute 58% and
females 42% in the United States.19 A lower ESKD
incidence for females versus males was shown to occur
in nearly all countries.20 However, the incidence of
treated ESRD was approximately 1.8 to 2 times higher
for males in France, Belgium, all of the Nordic coun-
tries, and Spain. In contrast, Taiwan reported only a
small difference in the incidence between males and
females (USRDS data), but Japan showed one of the
highest percentage differences in the percentage of
male versus female ESKD patients (males in Japan
makeup 69% of the ESKD population).15
Similar to developed countries, it has been noted
that the change in the main cause of ESKD in Oman has
been from chronic glomerulonephritis to diabetic ne-
phropathy.21,22 This may be attributed to changes in
socioeconomic status and lifestyle transitions over
recent decades.4,7,23 Based on national health surveys
done in Oman in the years 1991, 2000, and 2008, the
prevalence of diabetes among adults above 20 years of
age was 9.7%, 11.6%, and 12.3% respectively.24,25 The
prevalence of hypertension and diabetes is rising
disproportionately by more than 80% to 100% in
developing countries, whereas the rise in developed
countries is 20% to 50%.26 This is expected to signif-
icantly increase the incidence and prevalence of ESKD
in developing countries. Also, there is a major concern
that despite the high incidence and prevalence of dia-
betes in developing countries, the reported incidence
and prevalence of diabetic nephropathy is very much
underestimated, as the quality of data is not optimal,
nor is the quality of registry work of a good standard
uniformly around the world.32The present study has shown that there is a higher
number of patients with diabetic nephropathy being
treated with hemodialysis compared to those treated
with transplantation. This ﬁnding has been seen nearly
all over the world where individuals with diabetic
nephropathy and ESKD are less likely to get kidney
transplantation.27 In the developing countries, this
inequality tends to be even more obvious and very
striking in view of socioeconomic factors that affect the
management of ESKD patients.28 Our study ﬁndings
suggest poor access of diabetic patients to kidney
transplantation, as only a living-related kidney dona-
tion program is available in Oman, and risks of travel
for commercial transplantation or medical tourism is
costly, with a low probability of being offered an
organ.29
In Oman, the trend in the treated ESKD incidence
rate has shown a relatively stable annual progressive
rise throughout the years from 2000 to 2013, from an
overall 5% to just over 10% per year. The United
States displayed a relatively stable ESKD incidence rate
over this same time period, with an overall 9% increase
from 2000 to 2001 to that in 2012 to 2013, whereas it
was very high for Thailand (1210%), Russia (249%),
and the Republic of Korea (121%) (USRDS data).
In 2013, the Omani citizens were just over 2 million,
and the prevalence of treated ESKD was 1100 PMP.
However, other countries such as Taiwan, the United
States, Japan, Singapore, Portugal, and the Republic of
Korea showed a very high prevalence ranging from
1442 to 3138 PMP, with the lowest prevalence reported
in Indonesia, Bangladesh, South Africa, Philippines,
Russia, and Saudi Arabia, where the ESKD prevalence
ranged from 66 to 486 PMP (USRDS data).
Renal registries offer an important source of infor-
mation in characterizing the ESKD population16 and are
a valuable resource for information on the ability of the
health system to provide RRT. In addition, renal reg-
istries provide insights regarding the burden of kidney
disease, and allow comparisons with regional and in-
ternational registries to further improve the service and
to use whatever means are available to curtail the rising
incidence and prevalence of ESKD.
We noticed an uncommon observation that the
number of ESKD patients living with a kidney trans-
plant is almost equal to the number of patients treated
with hemodialysis. In Oman, which has exclusively a
living-related kidney transplant donation program, this
program contributes 22.7% of the kidney trans-
plantations for all of the ESKD patients living with a
kidney transplant within Oman. This has been the
result of commercial transplantation from various
developing countries. Deceased donor programsKidney International Reports (2017) 2, 27–35
Table 1. Dialysis facilities in Oman
Name of dialysis unit Number of beds Starting year
1. Sultan Qaboos University Hospital, Muscat 2 1987
2. Royal Hospital, Muscat 6 1987
3. Sohar Hospital 12-14 (26) 19911997
4. Sultan Qaboos Hospital, Salalah 22 1992
5. Ibra Hospital 16-9 (25) 19932006
6. Ibri Hospital 8 1995
7. Rustaq Hospital 8 1995
8. Khasab Hospital 3 1997
9. Nizwa Hospital 14 1998
10. Renal dialysis Center at Bausher, Muscat 42 1998
11. Sur Hospital 11 2002
12. Dibba Hospital 2 2003
13. Jaalan Bin Bu Ali 10 2005
14. Quriyat Hospital 5 2005
15. AlBuraimi Hospital 6 2008
16. Musannah renal dialysis center 14 2008
17. Samael renal dialysis center 8 2008
18. Sinaw Hospital 8 2011
Total number of beds 220 As of 2013
F Al Ismaili et al.: End-Stage Kidney Disease in Oman CLINICAL RESEARCHcontributed to only 1.3% of total transplanted cases in
Oman. However, 76% of kidney transplant cases are
commercial transplantations that are being done abroad
(unpublished data). This illegal pathway has led to an
almost equal number of transplant cases and hemodi-
alysis cases in the country. This has been driven by
various socioeconomic and cultural beliefs. As the
deceased donor program is still in its infancy, we
anticipate that it will increase and hence curtail the use
of commercial transplantations.29–31
All citizens have easy and free access to health ser-
vices all over the country.32 At the beginning, the
number of patients with ESKD was very small, and they
were sent to India for dialysis and lived there for the rest
of their lives. In 1983, those patients who were still
living in India were brought back to Oman when the
ﬁrst dialysis unit was established. The number of pa-
tients was small, and a single dialysis unit was sufﬁcient
for all patients across the country. In addition, all ser-
vices were provided for them, including transportation.
However, with the increasing number of patients and
rising prevalence of citizens with ESKD, Ministry Of
Health built new units to cope with the rising number of
patients. The location of new units were built in close
proximity to the majority of patients in each area.
Since 1970, Oman has undergone rapid socioeco-
nomic development along with demographic trends
that have been positively reﬂected in all sectors,
including the health service sector. Examples include a
rise in life expectancy at birth and a decline in the
frequency of infectious diseases. Free-of-charge health
services are provided to all citizens by the Ministry Of
Health with a total manpower of 40,240, including
6,305 registered physicians, 14,623 nurses, 1,701 labo-
ratory technicians, 346 dentists, 544 pharmacists, and
1,424 assistant pharmacists and 133 administrators
(Annual Health Report data, 2014). The Ministry Of
Health provides primary health care through 200
health care centers, secondary health care through 45
hospitals, and tertiary health care through 4 hospitals.
In recent years, Oman has been facing a rapid
change in the disease proﬁle, from ﬁrst-generation
diseases such as infectious diseases to non-
communicable diseases, including cardiovascular dis-
eases, diabetes, CKD, and cancer. In fact, the burden of
noncommunicable diseases has been a global public
health concern, with chronic disease accounting for
61% of global deaths and 49% of the worldwide
burden of disease.33 According to the World Health
Organization (WHO), CKD is the sixth main cause of
death in Oman, with a rate of 18.10 per 100,000 pop-
ulation (2.97% of total deaths). Oman was ranked 51st
among the top world countries in which CKD is a major
cause of death. In addition, 40% of inpatient and 55%Kidney International Reports (2017) 2, 27–35of outpatient morbidity in 2005 was caused by chronic
noncommunicable diseases, compared to 36% and 43%
in 1995.33 The prevalence of hypertension (deﬁned as
blood pressure $140/90 mm Hg) among individuals of
both sexes aged $20 years has increased considerably,
from 27% in 1995 to 32% in 2000.24,34 CKD is a global
issue and is ranked among the top 25 causes of years of
life lost due to premature mortality. In Oman, using
this ranking system, CKD was ranked 11th in 2010,
moving from its previous position of 22nd in 1990.35
Similarly, CKD was ranked 22nd within the top 25
causes of disability-adjusted life years in the Omani
population.35
The increased prevalence of ESKD is a true rise, a
good percentage of which possibly could be explained
by the increased accessibility of care. There has been a
rise in the accessibility of care because of the pro-
gressive increase in the number of health centers,
regional hospitals, and RDUs all over the Sultanate over
the past 30 years. However, since 1997, there has been
a greater rise especially with the registry, which has
been better maintained and developed. The true rise in
incidence is attributed to changes in diet, social habits,
and lifestyle, which have led to an increased incidence
of diabetes, hypertension, and dyslipidemia along with
a greater health awareness among Omani people. The
number of dialysis units reached a total of 18 units by
end of 2013 that worked 24 hours a day for at least 6
days a week. These units were distributed throughout
the country as close as possible to the majority of pa-
tients who needed these services (Table 1).
One limitation of this study is that the registry has
data available based only on patients who are able to33
CLINICAL RESEARCH F Al Ismaili et al.: End-Stage Kidney Disease in Omanaccess RRT, and not all those who have developed
ESKD. Therefore, this may underestimate the actual
number of ESKD cases within Oman. However, since
the health system provides free full universal medical
coverage for the citizens,32 this makes it less likely for
people not to seek medical treatment. Nonetheless,
nearly 50% of individuals living in Oman are non-
citizens from Asia and, in particular, from the Indian
subcontinent, with no free universal medical coverage.
Therefore, these individuals tend to return home for
permanent RRTs once they have developed ESKD, and
data for such cases are not reported to the registry.
Nonetheless, a sizable percentage of the population still
may die without reaching a health center or without
being diagnosed with ESKD. Therefore, this may
underestimate the incidence and prevalence and the
magnitude of the problem. In many developing coun-
tries such as those on the Indian subcontinent and sub-
Saharan Africa, a large percentage of patients who
develop ESKD are not offered RRT or do not have the
economic capability to sustain the treatment offered to
them.36–40 For example in India, only about 10% of
persons who developed ESKD could afford payment for
long-term RRT.26,28
Another problem is that poor documentation and
lack of continuity within a fragmented network of both
public and private providers may underestimate the
incidence and prevalence of health problems. However,
all patients are covered and paid for by the public
health system, even if they undergo dialysis at a pri-
vate clinic, which is only a single center in all of
Oman.32 Nonetheless, a good percentage of individuals
do go abroad for medical tourism, and some return
home to continue their therapy.29
In conclusion, the incidence and prevalence of
ESKD have increased progressively over 30 years. This
is anticipated to continue at an even higher rate in
view of the progressive rise in noncommunicable
diseases such as diabetes and hypertension. Contin-
uous improvement of the registry is required to
improve the capture rate and to provide even more
extensive and accurate data to the health authority
and to make the data available to the public to
enhance their awareness of the magnitude of this
health problem.
Developing countries must have proper data regis-
tries for ESKD, CKD, and RRT. This would further
strengthen their health care system and provide a
backbone for future planning and health resources
management to enable them to tackle the coming in-
crease in ESKD. All efforts should be made to curtail
the progression of noncommunicable diseases and
other factors that ultimately fuel the development of
ESKD.34DISCLOSURE
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SUPPLEMENTARY MATERIAL
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